Small therapeutic molecules for the treatment of inflammatory bowel disease

Gut

Volumn 50, Issue SUPPL. 3, 2002, Pages

  Van Deventer, S J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; ICOSANOID; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHODIESTERASE INHIBITOR; RIDOGREL; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ZILEUTON;

CONFERENCE PAPER; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; ENTERITIS; HUMAN; PRIORITY JOURNAL; REMISSION; SIGNAL TRANSDUCTION;

EID: 10844272960     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.50.suppl_3.iii47     Document Type: Conference Paper

References (140)

1. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease
2. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: A case-control study
3. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen
4. Spontaneous and continuous cyclooxygenase-2-dependent prostaglandin e(2) production by stromal cells in the murine small intestine lamina propria: Directing the tone of the intestinal immune response
5. COX-2: Promoting tolerance
6. Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis
7. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats
8. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis
9. Synergistic antiplatelet effect of ridogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor, and UDCG-212, a cAMP-phosphodiesterase inhibitor
10. Ridogrel: A selective inhibitor of the cytochrome P450-dependent thromboxane synthesis
11. Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application
12. Ridogrel, a dual thromboxane synthase inhibitor and receptor antagonist: Anti-inflammatory profile in inflammatory bowel disease
13. Ridogrel enemas in distal ulcerative colitis
14. PlateJet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees
15. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone
16. Release of platelet-activating factor (PAF) and accelerated healing induced by a PAF antagonist in an animal model of chronic colitis
17. Lexipafant (BB-882), a platelet activating factor receptor antagonist, ameliorates mucosal inflammation in an animal model of colitis
18. Platelet-activating factor mediates trinitrobenzene induced colitis
19. Increased nitric oxide synthesis in ulcerative colitis
20. Greatly increased luminal nitric oxide in ulcerative colitis
21. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease
22. High nitric oxide synthase activity in endothelial cells in ulcerative colitis
23. Expression of nitric oxide synthase in ulcerative colitis
24. Distribution of inducible nitric oxide synthase in ulcerative colitis
25. Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon
26. Expression of nitric oxide synthase in inflammatory bowel disease is not affected by corticosteroid treatment
27. Bacterial induction of inducible nitric oxide synthase in cultured human intestinal epithelia cells
28. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages
29. Peroxynitrite-induced rat colitis - A new model of colonic inflammation
30. The selective beneficial effects of nitric oxide inhibition in experimental colitis
31. Experimental colitis is ameliorated by inhibition of nitric oxide synthase activity
32. Time-dependent actions of nitric oxide synthase inhibition on colonic inflammation induced by trinitrobenzene sulphonic acid in rats
33. Inducible nitric oxide synthase attenuates chronic colitis in human histocompatibility antigen HLA-B27/human beta2 microglobulin transgenic rats
34. Inhibition of nitric oxide synthesis by aminoguanidine increases intestinal damage in the acute phase of rat TNB-colitis
35. Aminoguanidine has both an anti-inflammatory effect on experimental colitis and a proliferative effect on colonic mucosal cells
36. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats
37. The effect of inhibitors of inducible nitric oxide synthase on chronic colitis in the rhesus monkey
38. The physiological expression of inducible nitric oxide synthase (iNOS) in the human colon
39. PPARgamma, the ultimate thrifty gene
40. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
41. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
42. Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells
43. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse
44. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers
45. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies
46. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle
47. Pioglitazone
48. Rosiglitazone
49. Peroxisome proliferator-activated receptor gamma (PPARgamma) activation and its consequences in humans
50. Troglitazone and related compounds: Therapeutic potential beyond diabetes
51. Constitutive and inducible in vivo protein-DNA interactions at the tumor necrosis factor-alpha promoter in primary human T lymphocytes
52. Ceramide and cyclic adenosine monophosphate (cAMP) induce cAMP response element binding protein phosphorylation via distinct signaling pathways while having opposite effects on myeloid cell survival
53. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells
54. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees
55. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
56. Interactive effects of the tumor necrosis factor promoter and 3′-untranslated regions
57. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees
58. Effects of two methylxanthines, pentoxifylline and propentofylline, on arachidonic acid metabolism in platelets stimulated by thrombin
59. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor
60. Pentoxifylline inhibits ICAM-1 expression and chemokine production induced by proinflammatory cytokines in human pulmonary epithelial cells
61. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis
62. Regulation of IL-15-stimulated TNF-alpha production by rolipram
63. Tumour necrosis factor inhibitors reduce the acute-phase response in hapten-induced colitis
64. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity
65. Effect of acute pentoxifylline treatment in an experimental model of colitis
66. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis
67. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release
68. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice
69. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: In vitro anti-inflammatory actions
70. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo
71. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease
72. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease
73. Results of a double blind study of the influence of thalidomide on the lepra reaction
74. Further observation with thalidomide in lepra reactions
75. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
76. Differential effect of thalidomide and dexamethasone on the transcription factor NF-kappa B
77. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
78. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: Comparisons with dexamethasone
79. Thalidomide analogs and PDE4 inhibition
80. CC-3052: A water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production
81. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
82. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
83. A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans
84. Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection
85. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis
86. Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease
87. Thalidomide: Current and potential clinical applications
88. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial
89. Treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217)
90. Treatment of colitis in Behcet's disease with thalidomide
91. Pyoderma gangrenosum associated with Behcet's disease: Treatment with thalidomide
92. Thalidomide for the treatment of AIDS-associated wasting
93. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus
94. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
95. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial
96. Thalidomide in the treatment of refractory rheumatoid arthritis
97. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
98. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: Preliminary results
99. Thalidomide therapy for patients with refractory crohn's disease: An open-label trial
100. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
101. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
102. Processing of tumour necrosis factor-alpha precursor by metalloproteinases
103. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor
104. Matrix metalloproteinases and processing of pro-TNF-alpha
105. The metalloproteinase inhibitor GI5402 inhibits endotoxin-induced soluble CD27 and CD16 release in healthy humans
106. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme
107. Intracellular maturation and localization of the tumour necrosis factor alpha convertase (TACE)
108. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia
109. Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease
110. Suppression of T cell-mediated injury in human gut by interleukin 10: Role of matrix metalloproteinases
111. Regulation of matrix metalloproteinases in human intestinal mucosa
112. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease
113. Ongoing trials with matrix metalloproteinase inhibitors
114. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures
115. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
116. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells
117. Molecular cloning of human p38 MAP kinase
118. LPS induction of gene expression in human monocytes
119. Signal transduction by the JNK group of MAP kinases
120. Regulation of NF-kappa B activation by MAP kinase cascades
121. The JNK and P38 MAP kinase signaling pathways in T cell-mediated immune responses
122. IkappaB-NF-kappaB structures: At the interface of inflammation control
123. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses
124. Activation of nuclear factor kappa B inflammatory bowel disease
125. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa
126. NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria
127. Mediation by Nf-kappa-B of cytokine induced expression of intercellular adhesion molecule 1 (Icam-1) in an intestinal epithelial cell line, a process blocked by proteasome inhibitors
128. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination
129. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
130. Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis
131. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB
132. Curcumin blocks cytokine-mediated NF-kappa B activation and proinftammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity
133. Germinated barley foodstuffs attenuate colonic mucosal damage and mucosal nuclear factor kappa B activity in a spontaneous colitis model
134. Butyrate inhibits inflammatory responses through NFkappaB inhibition: Implications for Crohn's disease
135. Differential activity and expression of mitogen-activated protein kinases in inflammatory bowel disease
136. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
137. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function
138. Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells
139. p38MAP kinase is a negative regulator for ERK1/2-mediated growth of AIDS-associated Kaposi's sarcoma cells
140. A new MAP kinase inhibitor, CNI 1493, is safe and effective in the treatment of moderate to severe Crohn's disease